(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Track down the Ideal Weight reduction Methodology for Your Way of life - 2The Significance of Health Projects in Senior Protection.
- 3Abbott issues US device correction for some glucose monitors over faulty readings risk
- 4NASA just launched Artemis 2. What happens today could make or break the moon mission
- 5'We are ready': NASA still on track to launch Artemis 2 astronauts to the moon April 1
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Family-Accommodating Snow Sports Experiences
- How do my eyes adjust to the dark and how long does it take?
- Earth’s magnetic field protects life on Earth from radiation, but it can move, and the magnetic poles can even flip
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- This ‘CSI: Miami’ star spent years solving crimes on TV. Then she became the target of one herself.
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- Day to day Temporary Positions That Compensate Fairly in the US
- 'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here
